OTCMKTS:STXS - Stereotaxis Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.2515 -0.03 (-2.34 %)
(As of 01/20/2019 11:50 AM ET)
Previous Close$1.2515
Today's Range$1.2515 - $1.28
52-Week Range$0.5130 - $1.65
Volume15,179 shs
Average Volume23,973 shs
Market Capitalization$73.91 million
P/E RatioN/A
Dividend YieldN/A
Beta1.43
Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.

Receive STXS News and Ratings via Email

Sign-up to receive the latest news and ratings for STXS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:STXS
Previous SymbolNASDAQ:STXS
CUSIPN/A
Phone314-678-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.14 million
Cash Flow$0.0865 per share
Book Value($1.16) per share

Profitability

Net Income$-5,880,000.00

Miscellaneous

Employees117
Market Cap$73.91 million
OptionableNot Optionable

Stereotaxis (OTCMKTS:STXS) Frequently Asked Questions

What is Stereotaxis' stock symbol?

Stereotaxis trades on the OTCMKTS under the ticker symbol "STXS."

How were Stereotaxis' earnings last quarter?

Stereotaxis Inc (OTCMKTS:STXS) posted its earnings results on Monday, November, 12th. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter. The medical equipment provider had revenue of $7.56 million for the quarter. Stereotaxis had a negative return on equity of 15.17% and a negative net margin of 6.30%. View Stereotaxis' Earnings History.

When is Stereotaxis' next earnings date?

Stereotaxis is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Stereotaxis.

What guidance has Stereotaxis issued on next quarter's earnings?

Stereotaxis updated its FY 2018 earnings guidance on Monday, November, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $28-28 million.

Has Stereotaxis been receiving favorable news coverage?

Press coverage about STXS stock has been trending extremely positive on Sunday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Stereotaxis earned a coverage optimism score of 4.1 on InfoTrie's scale. They also gave news articles about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days.

Who are some of Stereotaxis' key competitors?

Who are Stereotaxis' key executives?

Stereotaxis' management team includes the folowing people:
  • Mr. David Leo Fischel CFA, CPA, CEO & Chairman (Age 31)
  • Mr. Martin C. Stammer, Chief Financial Officer (Age 38)
  • Mr. Kevin M. Barry, Chief Legal Officer, Corp. Sec. & Chief Compliance Officer
  • Dr. Gery Tomassoni M.D., FHRS, Chief Medical Officer
  • Dr. J. David Burkhardt, Chief Devel. Advisor

How do I buy shares of Stereotaxis?

Shares of STXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Stereotaxis' stock price today?

One share of STXS stock can currently be purchased for approximately $1.2515.

How big of a company is Stereotaxis?

Stereotaxis has a market capitalization of $73.91 million and generates $31.14 million in revenue each year. Stereotaxis employs 117 workers across the globe.

What is Stereotaxis' official website?

The official website for Stereotaxis is http://www.stereotaxis.com.

How can I contact Stereotaxis?

Stereotaxis' mailing address is 4320 FOREST PARK AVENUE SUITE 100, ST.LOUIS MO, 63108. The medical equipment provider can be reached via phone at 314-678-6100 or via email at [email protected]


MarketBeat Community Rating for Stereotaxis (OTCMKTS STXS)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  81 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  180
MarketBeat's community ratings are surveys of what our community members think about Stereotaxis and other stocks. Vote "Outperform" if you believe STXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2019 by MarketBeat.com Staff

Featured Article: Swap

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel